Last updated: October 11, 2021
Sponsor: University Hospital, Montpellier
Overall Status: Active - Recruiting
Phase
N/A
Condition
Primary Immunodeficiency
Primary Immunodeficiency Disorders
Hypogammaglobulinemia
Treatment
N/AClinical Study ID
NCT04356053
RECHMPL20_0199
Ages 1-16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion criteria:
- Subject aged 1 month to 16 years.
- Admission in pediatric ICU for more than 24h.
- Documented severe infection (bacterial, viral, fungal).
- Child benefiting from a social security scheme.
- Collection of parental consent / legal representatives.
Exclusion
Exclusion criteria:
- Prematurity (gestational age <37 weeks of gestation) up to 6 months of age.
- Undocumented severe infections.
- Children entered for isolated RSV bronchiolitis, with no other infectious relatedcomplications.
- Previous comorbidity explaining the infection and/or the stay in intensive care /continuous care: known primary or secondary immunodeficiency; burned; risk factors forstatus epilepticus (encephalopathy, known epilepsy, head trauma), pneumonia or asthma (swallowing disorders, tracheotomy, chronic pulmonary pathology, asthma), meningitis (cochlear implants, breccia, neuromeningeal material), deep infection (implantedmaterial, recent surgery), cardiovascular decompensation.
- Any other chronic pathology favoring an infection
- Impossibility to obtain the consent of parents / legal representatives.
Study Design
Total Participants: 90
Study Start date:
April 01, 2020
Estimated Completion Date:
December 30, 2021
Study Description
Connect with a study center
Uhmontpellier
Montpellier, 34295
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.